Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-trans retinoic acid plus decitabine for refractory cancer treatment-induced thrombocytopenia
ChiCTR2500099667Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tretinoin and decitabine, sponsored by Henan Cancer Hospital. Primary endpoint: Response rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tretinoindecitabine
Beyond the preview
Go deeper on ChiCTR2500099667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099667.